Lipoprotein(a) – Medxy AI

Oxidized Phospholipids on ApoB-100: Dissecting the Link Between Lipoprotein(a), Platelet Reactivity, and Long-Term Cardiovascular Risk

By MedXY 12/30/2025

This evidence-based analysis of the EXCELSIOR trial explores the relationship between OxPL-apoB, platelet activation, and long-term outcomes, finding that while these phospholipids predict major cardiovascular events, they do not appear to mediate their risk through direct platelet reactivity pathways.

Cardiology Internal Medicine news

Alirocumab Neutralizes the Pro-inflammatory Risk of Oxidized Phospholipids After Acute Coronary Syndrome

By MedXY 12/25/2025

A secondary analysis of the ODYSSEY OUTCOMES trial reveals that oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) independently predict cardiovascular risk in ACS patients, particularly when Lp(a) levels are low. Treatment with alirocumab effectively mitigates this risk while significantly reducing biomarker levels.

Cardiology Clinical Updates news

Evaluating AHA PREVENT Equations and Lipoprotein(a) in Cardiovascular Risk Stratification: Integrative Insights from MESA and UK Biobank Cohorts

By MedXY 12/03/2025

This review synthesizes evidence on the performance of AHA PREVENT equations in individuals with elevated lipoprotein(a), emphasizing its independent risk association and potential to enhance personalized ASCVD risk prediction.

Cardiology news

High Lipoprotein(a) Predicts Recurrent ASCVD — Intensified LDL‑Lowering, Especially PCSK9 Inhibitors, May Attenuate Risk

By MedXY 12/02/2025

In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most notably PCSK9 inhibitors.

Cardiology Neurology news

Lipoprotein(a) and Dementia: Large Cohorts Show No Clear Link — But Small Apo(a) Isoforms May Raise Alzheimer’s Risk

By MedXY 11/28/2025

A pooled analysis of three large cohorts found no consistent association between circulating lipoprotein(a) and Alzheimer’s disease or vascular dementia, but genetic evidence for very small apo(a) isoforms suggests a modest increase in Alzheimer’s risk.

Cardiology Neurology Specialties

Long-Term Stroke Risk in Healthy Women: The Predictive Role of hsCRP, LDL Cholesterol, and Lipoprotein(a)

By MedXY 10/22/2025

A 30-year prospective study reveals that elevated hsCRP, LDL cholesterol, and lipoprotein(a) levels independently and collectively increase the risk of ischaemic stroke in healthy women, advocating for early biomarker screening in stroke prevention.

Cardiology Specialties

Lipoprotein(a) as a Prognostic Indicator for Extracoronary Atherosclerotic Disease Progression: Insights from the UK Biobank

By MedXY 09/06/2025

Elevated lipoprotein(a) levels significantly predict incident peripheral artery disease and carotid stenosis, as well as progression to major limb events, underscoring its value as a prognostic biomarker for extracoronary atherosclerotic vascular complications.

Cardiology Clinical Updates Medical News Neurology Specialties

Lipoprotein(a) as an Independent Predictor of Peripheral Artery Disease and Carotid Stenosis: Insights from a Large UK Biobank Study

By MedXY 08/01/2025

A landmark UK Biobank study demonstrates that elevated lipoprotein(a) independently predicts both the onset and progression of peripheral artery disease and carotid stenosis, beyond traditional cardiovascular risk factors.